Dec 2 (Reuters) - Mesoblast Ltd MSB.AX :
* FDA GRANTS FAST TRACK DESIGNATION FOR REMESTEMCEL-L IN THE TREATMENT OF ACUTE RESPIRATORY DISTRESS SYNDROME DUE TO COVID-19
Dec 2 (Reuters) - Mesoblast Ltd MSB.AX :
* FDA GRANTS FAST TRACK DESIGNATION FOR REMESTEMCEL-L IN THE TREATMENT OF ACUTE RESPIRATORY DISTRESS SYNDROME DUE TO COVID-19